# Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

> **NCT06427798** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 66 (estimated)

## Conditions studied

- Somatostatin Receptor Positive
- Gastrointestinal Neuroendocrine Tumors
- Pheochromocytoma
- Paragangliomas

## Interventions

- **DRUG:** 68Ga-DOTATATE
- **DRUG:** [203Pb]VMT-alpha-NET
- **DRUG:** [212Pb]VMT-alpha-NET

## Key facts

- **NCT ID:** NCT06427798
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-07
- **Primary completion:** 2029-07-01
- **Final completion:** 2039-07-01
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06427798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06427798, "Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT06427798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*